Management of Hyperthyroidism in Pregnancy: Implications for Maternal and Fetal Outcomes
Saudi Journal of Medicine and Public Health · 2024
DOI: 10.64483/202412236 ↗Kurz gefasst
Fachartikel in der Zeitschrift Saudi Journal of Medicine and Public Health, 2024. Verfasst von Majdi Raji Nafaa Al-Harbi und 9 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Hyperthyroidism in pregnancy, while uncommon, poses significant risks to both maternal and fetal health. The most prevalent cause is Graves' disease, an autoimmune disorder driven by thyroid-stimulating antibodies (TRAbs) that can cross the placenta. Physiological changes of pregnancy often mask or mimic symptoms of thyrotoxicosis, complicating diagnosis and potentially delaying treatment.
Aim
This review aims to synthesize the etiology, pathophysiology, and evidence-based management of hyperthyroidism in pregnancy. It emphasizes optimizing maternal and fetal outcomes through timely diagnosis, appropriate treatment, and vigilant monitoring.
Methods
A comprehensive review of the clinical approach is presented, covering the initial evaluation using trimester-specific thyroid function tests, the role of TRAb measurement for diagnosis and fetal risk stratification, and the management principles using antithyroid drugs (ATDs). The importance of fetal surveillance through ultrasound and heart rate monitoring is also detailed.
Results
Proper management, primarily with antithyroid drugs, significantly improves outcomes. A treatment strategy of Propylthiouracil (PTU) in the first trimester, transitioning to Methimazole (MMI) thereafter, balances the risks of teratogenicity and hepatotoxicity. Uncontrolled disease is linked to miscarriage, preeclampsia, and fetal thyrotoxicosis, while overtreatment can cause fetal hypothyroidism. Fetal surveillance is critical when maternal TRAbs are elevated.
Conclusion
Successful management of hyperthyroidism in pregnancy requires a multidisciplinary approach to maintain maternal euthyroidism with the lowest effective ATD dose, while conducting ongoing fetal assessment to mitigate complications.
Zitieren
APA
Al-Harbi, M. R. N., Al-Awfi, A. A., Aljohani, A. A. B., Alharbi, A. S. H., Alharbi, W. S., Alsadi, N. M., Alhejaili, A. S., Aljohani, G. B., Alamri, S. A., & saib, A. H. (2024). Management of Hyperthyroidism in Pregnancy: Implications for Maternal and Fetal Outcomes. Saudi Journal of Medicine and Public Health. https://doi.org/10.64483/202412236
Vancouver
Al-Harbi MRN, Al-Awfi AA, Aljohani AAB, Alharbi ASH, Alharbi WS, Alsadi NM, et al. Management of Hyperthyroidism in Pregnancy: Implications for Maternal and Fetal Outcomes. Saudi Journal of Medicine and Public Health. 2024. doi:10.64483/202412236
BibTeX
@article{AlHarbi2024,
author = {Al-Harbi, Majdi Raji Nafaa and Al-Awfi, Amal Aqeel and Aljohani, Abrar Abdulkareem Bashir and Alharbi, Afrah Sayer H and Alharbi, Waad Salman and Alsadi, Nader Marshwood and Alhejaili, Ahmad Saud and Aljohani, Ghadeer bandar and Alamri, Seham Abdullah and saib, Alaa Hashim},
title = {Management of Hyperthyroidism in Pregnancy: Implications for Maternal and Fetal Outcomes},
journal = {Saudi Journal of Medicine and Public Health},
year = {2024},
doi = {10.64483/202412236}
}
EUVIMED